IM Ceftriaxone for Group B Streptococcus UTI
Yes, intramuscular ceftriaxone provides effective coverage for Group B Streptococcus urinary tract infections. Ceftriaxone demonstrates excellent in vitro activity against Group B Streptococcus (GBS) and achieves high urinary concentrations sufficient for treating UTIs caused by this organism.
Microbiological Coverage
Group B Streptococcus (Streptococcus agalactiae) is uniformly susceptible to ceftriaxone. Research demonstrates that GBS strains have minimal inhibitory concentrations (MICs) of 0.05-0.1 mg/L and minimal bactericidal concentrations of 0.1-0.4 mg/L for ceftriaxone 1. These values are well below achievable serum and urinary concentrations with standard dosing.
Clinical Evidence
Ceftriaxone achieves very high urinary levels following single daily doses and has demonstrated excellent clinical and bacteriologic results in UTIs caused by susceptible organisms 2. The drug's pharmacokinetic profile is particularly favorable for urinary tract infections, with substantial urinary excretion despite its dual biliary-renal elimination pathway 3.
Studies specifically examining ceftriaxone for UTIs show:
- Single-dose ceftriaxone (500 mg IM) achieved 92% cure rates for lower UTIs 4
- Single-dose therapy demonstrated 90% cure rates comparable to multi-day oral regimens 5
- Five-day courses showed superior efficacy (13/15 cases) for complicated UTIs 6
Dosing Recommendations
For adults with UTI caused by GBS:
- Uncomplicated cystitis: 500 mg IM single dose or 1 g IM/IV once daily
- Complicated UTI/pyelonephritis: 1-2 g IM/IV once daily for 7-14 days 3
For pediatric patients:
- 50-75 mg/kg once daily (not to exceed 2 g) for skin/soft tissue and most infections
- Administer over 60 minutes in neonates if given IV 3
Important Caveats
Neonatal Considerations
Ceftriaxone is contraindicated in premature neonates and in term neonates ≤28 days who require calcium-containing IV solutions due to risk of fatal ceftriaxone-calcium precipitation 3. However, for older infants and children, ceftriaxone is highly effective against GBS infections.
Enterococcal Coverage Gap
While ceftriaxone covers GBS excellently, it has NO activity against Enterococcus species 3. This is clinically relevant because:
- Ceftriaxone therapy for complicated UTIs increases risk of enterococcal re-infection (40/69 patients in one study) 7
- If polymicrobial infection with enterococci is suspected, add ampicillin or use alternative therapy 8
Clinical Context
The 2011 IDSA/ESMID guidelines for uncomplicated UTIs recommend ceftriaxone primarily as:
- An initial one-time IV dose (1 g) when fluoroquinolone resistance exceeds 10% 9
- For hospitalized patients with pyelonephritis requiring IV therapy 9
For GBS specifically, ceftriaxone is appropriate as definitive therapy once susceptibility is confirmed, not just as initial empiric coverage. The drug's once-daily dosing makes it particularly suitable for outpatient parenteral antibiotic therapy (OPAT) after initial stabilization.
Route of Administration
Both IM and IV routes are equally effective. IM administration is appropriate for outpatient treatment and requires injection into a large muscle mass with aspiration to avoid intravascular injection 3. The IM route achieves therapeutic levels comparable to IV administration for UTI treatment.